Actinium Pharmaceuticals Q3 Loss, Revenue, Stock Update

Actinium Pharmaceuticals, a New York-based cancer drug developer, reported a net loss of $5.1 million, or $0.16 per share, for the third quarter. The company generated $90,000 in revenue during the same period. Shares of Actinium Pharmaceuticals closed at $1.27 on Friday, down from $1.65 a year ago. These financial reports offer transparency into the companys operational costs and income as it continues its work in cancer drug development.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.